TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07867886: The ODYSSEY Study: An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM

Sponsor: Boston Scientific Corporation · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$13,028,400

Rescue Site Savings

+$8,593,200

Unlock Full NCT07867886 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07867886 Rescue Dossier →